PROK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-39.40K

-151.84%

-0.151

-11.01%

0.00

-100%

-0.160

+23.08%

-0.170

+30.77%

Estimates Revision

The market is revising Upward the revenue expectations for ProKidney Corp. (PROK) for FY2025, with the revenue forecasts being adjusted by 10.41% over the past three months. During the same period, the stock price has changed by -22.52%.

Revenue Estimates for FY2025

Revise Upward

+10.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+43.37%

In Past 3 Month

Stock Price

Go Down

-22.52%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 4.67 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

1 Sell

Hold

Current: 0.000

Low

1.00

Averages

4.67

High

10.00

Current: 0.000

Low

1.00

Averages

4.67

High

10.00

H.C. Wainwright

Joseph Pantginis

Buy

initiated

$12

2025-12-16

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$12

2025-12-16

initiated

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney with a Buy rating and $12 price target. The company is pioneering an approach to postponing progressive kidney dysfunction, the analyst tells investors in a research note. The firm says ProKidney is a late clinical-stage biopharmaceutical company developing rilparencel, an investigational autologous cell therapy targeting patients with moderate to severe chronic kidney disease and type 2 diabetes. It believes rilparencel has the potential to redefine the therapeutic landscape of chronic kidney disease.

UBS

Buy

upgrade

$4 -> $8

2025-07-15

Reason

UBS

Price Target

$4 -> $8

2025-07-15

upgrade

Buy

Reason

UBS raised the firm's price target on ProKidney to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.

Guggenheim

Buy

maintain

$6 -> $7

2025-07-14

Reason

Guggenheim

Price Target

$6 -> $7

2025-07-14

maintain

Buy

Reason

Guggenheim raised the firm's price target on ProKidney to $7 from $6 and keeps a Buy rating on the shares. Guggenheim says it was "very surprised" by the move in ProKidney shares last week following an "encouraging but somewhat incremental" data release on Tuesday from the rilparencel Phase 2 REGEN-007 trial, and tells investors in a research note that the firm was surprised by the enthusiasm experts showed for rilparencel following this data update. The firm awaits next month's regulatory update after the company's Type B Meeting with the FDA, and the full REGEN-007 data presentation at the American Society of Nephrology Meeting in November.

Citi

Buy

upgrade

$6 -> $9

2025-07-08

Reason

Citi

Price Target

$6 -> $9

2025-07-08

upgrade

Buy

Reason

Citi raised the firm's price target on ProKidney to $9 from $6 and keeps a Buy rating on the shares after the company reported results from the Phase 2 REGEN-007 study evaluating rilparencel in diabetes and chronic kidney disease. The firm says the initial data exceeded Citi's and management's expectations. REGEN-007 demonstrated statistically significant efficacy in group one, which may support accelerated approval in Phase 3 pending FDA confirmation, the analyst tells investors in a research note. Citi upped its probability of sucess for REGEN-007 to 60% from 50%.

BofA

Jason Gerberry

Neutral -> Underperform

downgrade

$3 -> $1

2025-06-30

Reason

BofA

Jason Gerberry

Price Target

$3 -> $1

2025-06-30

downgrade

Neutral -> Underperform

Reason

BofA analyst Jason Gerberry downgraded ProKidney to Underperform from Neutral with a price target of $1, down from $3.

BofA

Neutral -> Underperform

downgrade

$3 -> $1

2025-06-30

Reason

BofA

Price Target

$3 -> $1

2025-06-30

downgrade

Neutral -> Underperform

Reason

BofA downgraded ProKidney to Underperform from Neutral with a price target of $1, down from $3. The downgrade reflects more conservative peak sales for REACT, the company's sole product candidate in development for treatment of diabetic chronic kidney disease, the analyst tells investors in a research note. Recent discussions with nephrology experts suggest changes in the competitive landscape and the REACT program, warranting more segmentation-related "haircuts" and reducing the total addressable market, the firm says. The risk/reward skews to the downside with a financing overhang and limited value-inflection catalysts, BofA argues.

Valuation Metrics

The current forward P/E ratio for Prokidney Corp (PROK.O) is -3.48, compared to its 5-year average forward P/E of -5.39. For a more detailed relative valuation and DCF analysis to assess Prokidney Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.39

Current PE

-3.48

Overvalued PE

-0.46

Undervalued PE

-10.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.73

Current EV/EBITDA

-9.10

Overvalued EV/EBITDA

-2.89

Undervalued EV/EBITDA

-10.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

-249.01

Current PS

-8011.33

Overvalued PS

1438.45

Undervalued PS

-1936.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 503.05% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 503.05% over the last month.

Sold

Bought

PROK News & Events

Events Timeline

No data

News

3.5

2025-12-16PRnewswire

Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing

3.5

2025-12-16Newsfilter

Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing

9.5

2025-11-11NASDAQ.COM

PROKIDNEY CORP. Reports Smaller Q3 Loss, Surpassing Expectations

People Also Watch

Frequently Asked Questions

What is Prokidney Corp (PROK) stock price today?

The current price of PROK is 2.34 USD — it has decreased -0.85 % in the last trading day.

What is Prokidney Corp (PROK)'s business?

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

What is the price predicton of PROK Stock?

What is Prokidney Corp (PROK)'s revenue for the last quarter?

Prokidney Corp revenue for the last quarter amounts to 217.00K USD, decreased % YoY.

What is Prokidney Corp (PROK)'s earnings per share (EPS) for the last quarter?

Prokidney Corp. EPS for the last quarter amounts to -0.12 USD, decreased -14.29 % YoY.

What changes have occurred in the market's expectations for Prokidney Corp (PROK)'s fundamentals?

How many employees does Prokidney Corp (PROK). have?

Prokidney Corp (PROK) has 204 emplpoyees as of January 10 2026.

What is Prokidney Corp (PROK) market cap?

Today PROK has the market capitalization of 703.95M USD.